GLUE
VENTE TOTALE: 19 500 titres (~451 318,55 $ US)
- Insiders
- Warmuth Markus, Manning Anthony M.
- Total bought
- —
- Total sold
- $451,319
- Last activity
- —
- Last synced
-
2026-07-29 15:28:58
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Neutral signal Scored 2026-07-29
GLUE presents a structurally weak fundamental profile: despite adequate near-term liquidity (score: 85), persistent negative operating margins, heavy cash burn from R&D/SG&A, and a poor fundamental trend score (35)…
The first sentence of the analysis written for GLUE on 2026-07-29 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 93.2% | 89.3% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | -32.1% | -92.7% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | -25.4% | -82.0% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | -43.8% | -107.3% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | -32.1% | -92.7% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | -31.2% | -96.1% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | -31.2% | -96.1% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | -31.2% | -96.1% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 6.123 | 2.405 | 5.070 | 10.790 | 20.956 | |
| Quick Ratio | 6.123 | 2.405 | 5.070 | 10.790 | 20.956 | |
| Solvency Ratio | -0.140 | -0.299 | -1.037 | -1.476 | -3.818 | |
| Cash Ratio | 2.023 | 1.429 | 2.749 | 2.148 | 20.800 | |
| Price To Earnings Ratio | -34.087 | -7.082 | -2.148 | -3.309 | -12.843 | |
| Price To Earnings Growth Ratio | 0.642 | 0.113 | -0.150 | -0.074 | -0.137 | |
| Forward Price To Earnings Growth Ratio | 0.642 | 0.113 | -0.150 | -0.074 | -0.137 | |
| Price To Book Ratio | 5.589 | 2.301 | 1.620 | 1.324 | 2.734 | |
| Price To Sales Ratio | 10.532 | 6.783 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -47.369 | 13.495 | -4.621 | -3.411 | -13.753 | |
| Price To Operating Cash Flow Ratio | -57.135 | 12.214 | -6.630 | -3.887 | -16.008 | |
| Debt To Assets Ratio | 0.087 | 0.097 | 0.152 | 0.137 | 0.000 | |
| Debt To Equity Ratio | 0.168 | 0.192 | 0.257 | 0.173 | 0.000 | |
| Debt To Capital Ratio | 0.144 | 0.161 | 0.204 | 0.148 | 0.000 | |
| Long Term Debt To Capital Ratio | 0.130 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.925 | 1.968 | 1.695 | 1.262 | 1.054 | |
| Working Capital Turnover Ratio | 0.450 | 0.369 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -0.355 | 0.268 | -0.940 | -3.616 | -3.568 | |
| Operating Cash Flow Sales Ratio | -0.184 | 0.555 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.206 | 0.905 | 1.435 | 1.140 | 1.164 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | -26.831 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | -29.858 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -0.582 | 0.983 | -0.951 | -1.967 | 0.000 | |
| Capital Expenditure Coverage Ratio | -4.851 | 10.531 | -2.300 | -7.162 | -6.100 | |
| Dividend Paid And Capex Coverage Ratio | -4.851 | 10.531 | -2.300 | -7.162 | -6.100 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -38.635 | -5.344 | -1.618 | -3.480 | -8.412 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 93.2% | ▲4.0% | ▲56.7% |
| Ebit Margin | -32.1% | ▲60.6% | ▼-7.1% |
| Ebitda Margin | -25.4% | ▲56.6% | ▼-3.9% |
| Operating Profit Margin | -43.8% | ▲63.4% | ▼-13.6% |
| Pretax Profit Margin | -32.1% | ▲60.6% | ▼-7.1% |
| Continuous Operations Profit Margin | -31.2% | ▲64.9% | ▼-5.8% |
| Net Profit Margin | -31.2% | ▲64.9% | ▼-5.8% |
| Bottom Line Profit Margin | -31.2% | ▲64.9% | ▼-5.8% |
| Current Ratio | 6.123 | ▲3.718 | ▼-2.946 |
| Quick Ratio | 6.123 | ▲3.718 | ▼-2.946 |
| Solvency Ratio | -0.140 | ▲0.159 | ▲1.214 |
| Cash Ratio | 2.023 | ▲0.594 | ▼-3.807 |
| Price To Earnings Ratio | -34.087 | ▼-27.005 | ▼-22.193 |
| Price To Earnings Growth Ratio | 0.642 | ▲0.529 | ▲0.564 |
| Forward Price To Earnings Growth Ratio | 0.642 | ▲0.529 | ▲0.564 |
| Price To Book Ratio | 5.589 | ▲3.288 | ▲2.875 |
| Price To Sales Ratio | 10.532 | ▲3.749 | ▲7.069 |
| Price To Free Cash Flow Ratio | -47.369 | ▼-60.865 | ▼-36.237 |
| Price To Operating Cash Flow Ratio | -57.135 | ▼-69.349 | ▼-42.846 |
| Debt To Assets Ratio | 0.087 | ▼-0.010 | ▼-0.007 |
| Debt To Equity Ratio | 0.168 | ▼-0.023 | ▲0.010 |
| Debt To Capital Ratio | 0.144 | ▼-0.017 | ▲0.013 |
| Long Term Debt To Capital Ratio | 0.130 | ▲0.130 | ▲0.104 |
| Financial Leverage Ratio | 1.925 | ▼-0.043 | ▲0.344 |
| Working Capital Turnover Ratio | 0.450 | ▲0.081 | ▲0.286 |
| Operating Cash Flow Ratio | -0.355 | ▼-0.623 | ▲1.287 |
| Operating Cash Flow Sales Ratio | -0.184 | ▼-0.740 | ▼-0.259 |
| Free Cash Flow Operating Cash Flow Ratio | 1.206 | ▲0.301 | ▲0.036 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | ▲5.366 |
| Interest Coverage Ratio | 0.000 | 0.000 | ▲5.971 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -0.582 | ▼-1.565 | ▼-0.078 |
| Capital Expenditure Coverage Ratio | -4.851 | ▼-15.381 | ▼-2.874 |
| Dividend Paid And Capex Coverage Ratio | -4.851 | ▼-15.381 | ▼-2.874 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -38.635 | ▼-33.291 | ▼-27.137 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $1.30B | $512.9M | $290.4M | $359.4M | $950.3M | |
| Enterprise value | $1.21B | $331.4M | $208.3M | $351.5M | $604.2M | |
| EV / Sales | 9.80x | 4.38x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | -53.16x | 7.89x | -4.76x | -3.80x | -10.18x | |
| EV / Free cash flow | -44.07x | 8.72x | -3.31x | -3.34x | -8.74x | |
| EV / EBITDA | -38.63x | -5.34x | -1.62x | -3.48x | -8.41x | |
| Net debt / EBITDA | 2.89x | 2.93x | 0.64x | 0.08x | 4.82x | |
| Current ratio | 6.12x | 2.40x | 5.07x | 10.79x | 20.96x | |
| Income quality | 0.59x | -0.58x | 0.32x | 0.85x | 0.80x | |
| Graham net-net | $2 | $2 | $2 | $4 | $7 | |
| Tax burden | 97.2% | 103.7% | 100.3% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 103.6% | 100.0% | |
| Working capital | $329.0M | $220.5M | $189.6M | $250.3M | $332.0M | |
| Invested capital | $379.3M | $276.8M | $252.2M | $312.2M | $344.4M | |
| Return on assets | -8.6% | -16.6% | -44.6% | -31.7% | -20.2% | |
| Operating ROA | -12.2% | -21.8% | -44.4% | -31.7% | -35.1% | |
| Return on tangible assets | -8.6% | -16.6% | -44.6% | -31.7% | -20.2% | |
| Return on equity | -16.6% | -32.6% | -75.5% | -40.0% | -21.3% | |
| Return on invested capital | -13.6% | -28.4% | -55.1% | -35.1% | -20.8% | |
| Return on capital employed | -14.1% | -28.8% | -55.7% | -35.5% | -20.8% | |
| Earnings yield | -3.0% | -14.2% | -46.6% | -30.2% | -7.8% | |
| Free cash flow yield | -2.1% | 7.4% | -21.6% | -29.3% | -7.3% | |
| Capex / Op. cash flow | -20.6% | 9.5% | -43.5% | -14.0% | -16.4% | |
| Capex / Depreciation | 56.2% | 49.1% | 306.0% | 344.8% | 456.5% | |
| Capex / Sales | 3.8% | 5.3% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 29.4% | 46.5% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 114.4% | 160.8% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 15.3% | 24.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 14d | 1d | 0d | 0d | 0d | |
| Days payables outstanding | 155d | 774d | 654d | 0d | 0d | |
| Operating cycle | 14d | 1d | 0d | 0d | 0d | |
| Cash conversion cycle | -141d | -773d | -654d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+153.9%EV / Sales ▲+123.6%EV / EBITDA ▼-622.9%EV / Op. cash flow ▼-61.048Earnings yield ▲+0.112
Profitability
Return on equity ▲+0.160Return on assets ▲+0.080Return on invested capital ▲+0.149Return on capital employed ▲+0.147Operating ROA ▲+0.096Income quality ▲+1.168Tax burden ▼-0.064
Efficiency
Days sales outstanding ▲+12.741Days payables outstanding ▼-618.663Operating cycle ▲+12.741Cash conversion cycle ▲+631.405Capex / Sales ▼-0.015R&D / Sales ▼-0.463
Balance-sheet strength
Current ratio ▲+3.718Net debt / EBITDA ▼-0.036Working capital ▲+108479000.000Invested capital ▲+102537000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▲+37.1%EV / Sales n/aEV / EBITDA ▼-359.3%EV / Op. cash flow ▼-42.979Earnings yield ▲+0.048
Profitability
Return on equity ▲+0.047Return on assets ▲+0.116Return on invested capital ▲+0.073Return on capital employed ▲+0.067Operating ROA ▲+0.228Income quality ▼-0.212Tax burden ▼-0.028
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▼-14.833Net debt / EBITDA ▼-1.927Working capital ▼-3055000.000Invested capital ▲+34992000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-07-02 Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the grant of inducement equity awards to three newly hired non-executive employees as a material inducement to commencing their employment with the Company. The employees received, in the aggregate, non-qualified stock options to purchase 18,025 shares of Monte Rosa Therapeutics common stock, par value $0.0001 per share, with an exercise price per share equal to the closing price of $24.02 as reported by Nasdaq on July 1, the effective date of the grant or the “Grant Date”, which will vest 25% on the first anniversary of the Grant Date and in 36 equal monthly installments thereafter, subject to the employee's continued service with the Company through each applicable vesting date; and restricted stock units for an aggregate of 3,900 shares of Monte Rosa Therapeutics common stock, which will vest 25% on each of the first four anniversaries of the Grant Date, subject to the employee's continued service with the Company through each applicable vesting date, or collectively, the Awards.
- 2026-06-29 After a 400% Surge, Should Investors Care About This $882,000 Monte Rosa Insider Sale? This clinical-stage biotech focused on precision medicines reported a notable insider sale amid a year of exceptional share price gains.
- 2026-06-11 Monte Rosa: Initiating Coverage With A Buy On Degrader Platform Potential Monte Rosa Therapeutics, Inc. is a leading biotech in molecular glue degraders, with a $1.45bn valuation and robust partnerships with Novartis and Roche. GLUE's pipeline shows promising Phase 1 data, especially for MRT-8102 and MRT-6160, but lacks Phase 2 proof-of-concept results to fully derisk programs. Significant cash runway ($675m) and milestone-rich deals provide operational security while awaiting pivotal clinical readouts and potential Novartis milestones.
- 2026-06-02 Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the grant of inducement equity awards to four newly hired non-executive employees as a material inducement to commencing their employment with the Company. The employees received, in the aggregate, non-qualified stock options to purchase 20,050 shares of Monte Rosa Therapeutics common stock, par value $0.0001 per share, with an exercise price per share equal to the closing price of $19.67 as reported by Nasdaq on June 1, the effective date of the grant or the “Grant Date”, which will vest 25% on the first anniversary of the Grant Date and in 36 equal monthly installments thereafter, subject to the employee's continued service with the Company through each applicable vesting date; and restricted stock units for an aggregate of 4,400 shares of Monte Rosa Therapeutics common stock, which will vest 25% on each of the first four anniversaries of the Grant Date, subject to the employee's continued service with the Company through each applicable vesting date, or collectively, the Awards.
- 2026-05-20 Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences BOSTON, May 20, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences: TD Cowen 7th Annual Oncology Innovation Summit (virtual) – fireside chat, May 27, 2026, at 12:00 p.m. ET Jefferies Global Healthcare Conference in New York – fireside chat, June 4, 2026, at 11:40 a.m.
- 2026-05-07 Monte Rosa Therapeutics (GLUE) Reports Q1 Loss, Misses Revenue Estimates Monte Rosa Therapeutics (GLUE) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to earnings of $0.57 per share a year ago.
- 2026-05-07 Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates Interim clinical data from GFORCE-1 trial of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in subjects with elevated CVD risk; readout of expanded GFORCE-1 trial in subjects with elevated CVD risk anticipated in H2 2026 Company expects to initiate multiple MRT-8102 Phase 2 studies, including in patients with elevated atherosclerotic risk in H2 2026, in patients with gout flares in Q4 2026/Q1 2027, and in patients with moderate to severe hidradenitis suppurativa in H1 2027 Presented positive interim Phase 1/2 clinical data of GSPT1-directed MGD MRT-2359 in combination with an AR inhibitor in mCRPC patients with AR mutations; initiation of Phase 2 study evaluating MRT-2359 in combination with apalutamide in mCRPC patients with AR mutations planned for Q3 2026 VAV1-directed MGD MRT-6160 advancing toward anticipated initiation by Novartis of multiple Phase 2 studies in immune-mediated diseases Preclinical data presented at AACR highlight a novel cyclin E1-directed MGD with superior selectivity and reduced off-target activity compared to CDK2 inhibitors; IND submission anticipated in H2 2026 Strong balance sheet with cash, cash equivalents, restricted cash, and marketable securities of $671 million, expected to support operations into 2029 BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today reported business highlights and financial results for the first quarter ended March 31, 2026. “We continue to make excellent progress advancing multiple programs through the clinic, with all three of our clinical-stage programs approaching Phase 2 trial initiations,” said Markus Warmuth, M.D.
- 2026-05-05 Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the grant of inducement equity awards to four newly hired non-executive employees as a material inducement to commencing their employment with the Company. The employees received, in the aggregate, non-qualified stock options to purchase 38,925 shares of Monte Rosa Therapeutics common stock, par value $0.0001 per share, with an exercise price per share equal to the closing price of $18.80 as reported by Nasdaq on May 1, 2026, the effective date of the grant or the “Grant Date”, which will vest 25% on the first anniversary of the Grant Date and in 36 equal monthly installments thereafter, subject to the employee's continued service with the Company through each applicable vesting date; and restricted stock units for an aggregate of 8,550 shares of Monte Rosa Therapeutics common stock, which will vest 25% on each of the first four anniversaries of the Grant Date, subject to the employee's continued service with the Company through each applicable vesting date, or collectively, the Awards.
- 2026-04-21 Monte Rosa CEO Sells $141K in Stock Amid 300% Surge and Recent Capital Raise A GLUE executive disposed of 8,000 shares for a transaction value of approximately $141,000 at a weighted average price of around $17.64 per share on April 14, 2026. The sale represented 1.30% of their direct common stock holdings, reducing their directly held common shares from 613,471 to 605,471.
- 2026-04-20 Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors CCNE1-directed molecular glue degrader (MGD) induced deep tumor regressions in CCNE1-amplified in vivo models of ovarian, breast, and gastric cancers CCNE1-directed MGD demonstrated superior selectivity and reduced off-target activity compared to CDK2 inhibitors Oral presentation on April 21, 2026, at 2:30 p.m. PT BOSTON, April 20, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company will present preclinical data highlighting the potential of its highly selective, first-in-class cyclin E1 (CCNE1)-directed MGD, MRT-55811, to treat CCNE1-amplified solid tumors at the American Association for Cancer Research (AACR) Annual Meeting 2026, being held April 17-22 in San Diego, CA.